TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24395021
Drug: Guanfacine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (2 or 3 mg)
Study: 20694776
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs administered by both oral intake and retention enema (Group A)
Study: 20694776
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs given by retention enema only (Group B)
Study: 20694776
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Group C)
Study: 19080647
Drug: Oxaliplatin plus
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (40-45 Gy, 5 times a week)
Study: 19080647
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Control Group II)
Study: 19080647
Drug: Oxaliplatin plus
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for resectable patients)
Study: 19080647
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Control Group II for resectable patients)
Study: 19080647
Drug: Oxaliplatin plus
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for un-resectable patients)
Study: 19080647
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Control Group II for un-resectable patients)
Study: 18046028
Drug: Eltrombopag 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 30 mg daily
Study: 23497336
Drug: Eltrombopag (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (any dose)
Study: 8108576
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg a day for 3 consecutive days)
Study: 8108576
Drug: Clodronate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (300 mg a day for 3 consecutive days)
Study: 31491758
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin
Study: 29224823
Drug: Cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (20 mg/m2)
Study: 19541917
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RT)
Study: 19541917
Drug: Intensive comparison
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive comparison therapy (ICT)
Study: 17503984
Drug: Paroxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (60 mg/day)
Study: 15072661
Drug: Stepwise band-filling
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise band-filling during 6 monthly ambulant visits
Study: 29738877
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) 2 g orally 2 h preoperatively and two doses of 1 g TXA postoperatively
Study: 29738877
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 3 g administered in the operating room
Study: 29544472
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA)
Study: 29738877
Drug: Topical group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical group
Study: 21246842
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of rHuEpo at Zusanli (ST 36) and Shenshu (BL 23), 3 times a week for 2 months.
Study: 21246842
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of rHuEpo, 3 times a week for 2 months (Control group).
Study: 10408542
Drug: High-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose transdermal 17beta-estradiol (four skin patches each releasing 0.1 mg of estradiol daily, replaced every 2 to 3 days)
Study: 7579128
Drug: Mepyramine (histamine‐H1‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepyramine (histamine‐H1‐receptor antagonist) pretreatment
Study: 2123881
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate and human menopausal gonadotrophin (CC/HMG)
Study: 26027245
Drug: Etoricoxib (ET)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (ET) 90 mg continuously every day
Study: 26027245
Drug: Etoricoxib (ET)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (ET) 90 mg intermittently 1‐3 times weekly
Study: 23345574
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of prophylactic antibiotics
Study: 14871253
Drug: rFVIIa (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (90 microg/kg i.v.) given 3 h after idraparinux (7.5 mg s.c.)
Study: 14871253
Drug: rFVIIa (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (90 microg/kg i.v.) given 1 week after idraparinux (7.5 mg s.c.)
Study: 11528604
Drug: Multidisciplinary behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary behavioral treatment
Study: 7702020
Drug: Fructose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (50 g) added to a standard (40-g oral) fat load
Study: 2484836
Drug: Livingston's chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livingston's chemotherapy combined with isoprinosine
Study: 2484836
Drug: Livingston's chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livingston's chemotherapy with shortened treatment cycle (8 days) and isoprinosine
Study: 2484836
Drug: Livingston's chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livingston's chemotherapy (control group)
Study: 27101815
Drug: Fulranumab 6mg
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 6mg loading dose followed by 3mg (6mgLD+3mgQ4wk)
Study: 22169830
Drug: Lifestyle course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle course in combination with physical activity (intervention group)
Study: 20798560
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with bevacizumab (leucovorin, 5-fluorouracil plus irinotecan)
Study: 20798560
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (leucovorin, 5-fluorouracil plus irinotecan)
Study: 20798560
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with bevacizumab
Study: 16213302
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg, three times a day, 12 weeks)
Study: 16213302
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg, 2 weeks)
Study: 16213302
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous ganciclovir
Study: 10685331
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus oral estriol 4 mg/day for 4 months (add-back group; n = 6)
Study: 10685331
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot alone at a dose of 3.75 mg s.c. every month for 6 months (non add-back group; n = 6)
Study: 10685331
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus oral estriol add-back therapy
Study: 8763462
Drug: Lamisil (terbinafine)
Normalized name: Lamisil
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamisil (terbinafine) 250 mg/day
Study: 1811337
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet (200 g/d of lean Australian fish flesh)
Study: 1811337
Drug: Fish +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish + Oil diet (200 g/d of lean Australian fish flesh + 5 g/d fish oil)
Study: 6130658
Drug: Pindolol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.4 mg i.v.)
Study: 6130658
Drug: Metoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (5 mg i.v.)
Study: 6740566
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment (subcutaneous or intravenous)
Study: 22679142
Drug: Coumarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin treatment
Study: 30587933
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of Bbr with Fbt and Svt
Study: 29451825
Drug: Social Cognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Cognition and Object Relations Scale-Global Rating Method (SCORS-G)
Study: 27251185
Drug: Cranberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry beverage (240 mL/day)
Study: 24864125
Drug: TIV followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIV followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Study: 24864125
Drug: TIV followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIV followed by nonadjuvanted A(H1N1)pdm09 vaccine
Study: 24864125
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Study: 24864125
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by nonadjuvanted A(H1N1)pdm09 vaccine
Study: 20190704
Drug: Method C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method C (Integran, a sheet-type absorbable topical collagen hemostat)
Study: 20190704
Drug: Method G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method G (combined approach with TachoComb or PGA sheet fixed with fibrin glue)
Study: 17659194
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day with CYP3A4-MET statins
Study: 17659194
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day with non-CYP3A4-MET statins
Study: 17659194
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day with atorvastatin
Study: 20097702
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with atorvastatin
Study: 17659194
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day with pravastatin
Study: 12657846
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg intravenously every 12 h)
Study: 11140216
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicines
Study: 2064956
Drug: Daunorubicin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (two doses on the first 2 days of induction)
Study: 2064956
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without daunorubicin
Study: 2064956
Drug: Treatment continued
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment continued for 3 years
Study: 2064956
Drug: Treatment stopped
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment stopped after 2 years
Study: 2064956
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including all agents)
Study: 6367371
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg once daily
Study: 6367371
Drug: Captopril 25-50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25-50 mg 3 times daily
Study: 6367371
Drug: Captopril combined
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril combined with hydrochlorothiazide (25-50 mg)
Study: 6367371
Drug: Atenolol combined
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol combined with hydrochlorothiazide (25-50 mg)
Study: 24395497
Drug: Transradial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transradial intervention (TRI) and bivalirudin infusion
Study: 24395497
Drug: Transfemoral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transfemoral intervention (TFI) and unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI)
Study: 21465244
Drug: Control (CC)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CC)
Study: 15196153
Drug: RA/beta‐CD complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA/beta‐CD complex hydrogel formulation (0.025%)
Study: 15196153
Drug: RA/beta‐CD complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA/beta‐CD complex hydrogel formulation
Study: 15196153
Drug: RA/beta‐CD preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA/beta‐CD preparations
Study: 11772826
Drug: Levobupivacaine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (12 mg)
Study: 16430546
Drug: Bupivacaine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (12 mg)
Study: 11772826
Drug: Levobupivacaine (4-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (4-12 mg)
Study: 11772826
Drug: Bupivacaine (4-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (4-12 mg)
Study: 10586386
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (2 mg) with ketoconazole (200 mg) given 2 hours prior to probes
Study: 10586386
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (2 mg) with ketoconazole (200 mg) given simultaneously
Study: 10586386
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (2 mg)
Study: 8933995
Drug: Alniditan 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alniditan 1.2 mg
Study: 11531899
Drug: Alniditan 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alniditan 1.4 mg
Study: 10450538
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg mefloquine
Study: 1860148
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg mefloquine
Study: 6349649
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (300 mg/day)
Study: 27609756
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination antiretroviral therapy (cART)
Study: 24439714
Drug: FLUSH test
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUSH test (agitated saline solution flush)
Study: 23375921
Drug: Tooth-anchored treatment
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-anchored treatment group
Study: 23375921
Drug: Bone-anchored treatment
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-anchored treatment group
Study: 20646352
Drug: Propolis and
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis and zinc suspension
Study: 12954743
Drug: Buprenorphine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (16 mg) and Naloxone (4 mg)
Study: 12954743
Drug: Buprenorphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine alone (16 mg)
Study: 1577043
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release paracetamol 500 mg
Study: 1577043
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release paracetamol 1000 mg
Study: 1577043
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release paracetamol 2000 mg
Study: 3001149
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 6 g/d for 6 d
Study: 3001149
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DCHA) 6 g/d for 6 d
Study: 25491243
Drug: Text or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text or animated conversational agent
Study: 18672110
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (EE, IBU, PL)
Study: 15962651
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily for 30 weeks
Study: 8754377
Drug: Fraxiparin, antibiotic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparin, antibiotic, Metronidazole, and prostaglandins
Study: 2956865
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg enoximone
Study: 2956865
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg enoximone
Study: 7978427
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg enoximone
Study: 2956865
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg enoximone
Study: 2956865
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg enoximone
Study: 29562983
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for at least 6 months
Study: 21859733
Drug: Second-generation tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-generation tyrosine kinase inhibitors (nilotinib or dasatinib)
Study: 21859733
Drug: Interferon-α therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α therapy (control group)
Study: 17074639
Drug: AZD7009 (3‐hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 (3‐hour intravenous infusion)
Study: 9950305
Drug: Isoprinosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (50 mg/kg per day for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks)
Study: 31719010
Drug: Conventional non-antibiotic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-antibiotic suture
Study: 25335249
Drug: Care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care group (psychological treatment)
Study: 20855064
Drug: MMC (magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC (magnetic maneuverable capsule)
Study: 20855064
Drug: ESO2 (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO2 (conventional capsule)
Study: 17221169
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (20 mg) b.i.d for 3 months plus scaling and root planing (SRP)
Study: 17221169
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules b.i.d for 3 months plus scaling and root planing (SRP)
Study: 12926129
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + RT (three courses of chemotherapy followed by radiotherapy)
Study: 2349253
Drug: Cocaine-base 10
Normalized name: cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine-base 10 mg
Study: 2349253
Drug: Cocaine-base 20
Normalized name: cocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine-base 20 mg
Study: 2349253
Drug: Cocaine-base 40
Normalized name: cocaine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine-base 40 mg
Study: 106428
Drug: Ciclazindol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclazindol 50 mg orally
Study: 25366969
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose budesonide/formoterol (HDBF) 640/18 μg
Study: 25366969
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (BFMRT)
Study: 25366969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (terbutaline 1 mg)
Study: 25366969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lower dose budesonide/formoterol)
Study: 24398815
Drug: Computerised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised treatment group
Study: 18945254
Drug: ROSE-010 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 (both doses)
Study: 17763150
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (81, 162 and 325 mg/day for 4 weeks each)
Study: 16172177
Drug: Placebo-controlled intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled intervention, average trial size of 32 subjects at 5 dose levels.
Study: 16172177
Drug: Crossover designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crossover designs (more frequent in early publications) and parallel single-dose designs.
Study: 7383476
Drug: 1% econazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% econazole vaginal cream, used once daily at bedtime for 7 days